Oppenheimer Reaffirms Buy Rating for Recro Pharma (REPH)

Oppenheimer reissued their buy rating on shares of Recro Pharma (NASDAQ:REPH) in a research note issued to investors on Friday morning.

Several other brokerages have also recently issued reports on REPH. CIBC started coverage on shares of Recro Pharma in a research report on Wednesday, February 14th. They set an outperform rating and a $19.00 target price on the stock. Zacks Investment Research upgraded shares of Recro Pharma from a sell rating to a hold rating in a research report on Wednesday, March 21st. UBS started coverage on shares of Recro Pharma in a research report on Tuesday, February 13th. They set an outperform rating on the stock. Finally, ValuEngine upgraded shares of Recro Pharma from a sell rating to a hold rating in a research report on Thursday, March 1st. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Recro Pharma has a consensus rating of Buy and an average price target of $13.75.

How to Become a New Pot Stock Millionaire

Shares of Recro Pharma (NASDAQ:REPH) opened at $10.81 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.55 and a debt-to-equity ratio of 1.86. Recro Pharma has a 1 year low of $5.81 and a 1 year high of $12.23.

In related news, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of the stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $9.27, for a total value of $169,001.37. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total transaction of $2,014,000.00. The disclosure for this sale can be found here. Insiders sold a total of 246,364 shares of company stock worth $2,442,900 over the last three months. 21.60% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of REPH. Lyon Street Capital LLC purchased a new position in shares of Recro Pharma during the fourth quarter worth approximately $3,362,000. State Street Corp purchased a new position in shares of Recro Pharma during the second quarter worth approximately $1,047,000. Northern Trust Corp increased its position in shares of Recro Pharma by 428.5% during the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after acquiring an additional 144,676 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Recro Pharma by 787.4% during the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock worth $911,000 after acquiring an additional 114,960 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Recro Pharma by 14.2% during the second quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock worth $4,501,000 after acquiring an additional 79,520 shares during the period. 57.85% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Oppenheimer Reaffirms Buy Rating for Recro Pharma (REPH)” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3301664/oppenheimer-reaffirms-buy-rating-for-recro-pharma-reph.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liberum Capital Reiterates Hold Rating for Sports Direct
Liberum Capital Reiterates Hold Rating for Sports Direct
RWS  Rating Reiterated by Shore Capital
RWS Rating Reiterated by Shore Capital
WPP’s  Hold Rating Reiterated at Deutsche Bank
WPP’s Hold Rating Reiterated at Deutsche Bank
Berenberg Bank Raises Ten Entertainment Group  Price Target to GBX 310
Berenberg Bank Raises Ten Entertainment Group Price Target to GBX 310
Evonik Industries  Given a €27.00 Price Target by UBS Analysts
Evonik Industries Given a €27.00 Price Target by UBS Analysts
eMagin  Sees Large Decline in Short Interest
eMagin Sees Large Decline in Short Interest


© 2006-2018 Ticker Report. Google+.